Skill: atomus42/daily-prospection-intel (version 1.0.0)

# ArcaScience Daily Commercial Intelligence Report ## Description Generate a comprehensive daily commercial intelligence report identifying 8 actionable European regulatory opportunities for ArcaScience's BRA platform. Output as a professionally formatted .docx file. ## Trigger Use this skill when the user asks to: - Generate a daily prospection/intelligence report - Find commercial targets or opportunities in pharma - Research European regulatory developments for ArcaScience - Create a "pulse" or "intel" report - Run the daily prospection task Also triggered automatically by the `daily-prospection-intel` cron job. ## Instructions ### Phase 1: Research (Web Search Required) Search for the latest European regulatory developments from the past 24-48 hours. Run ALL of these searches: 1. **EMA/CHMP opinions**: Search `site:ema.europa.eu CHMP opinion 2026` and `EMA CHMP positive negative opinion this week` 2. **Marketing authorizations**: Search `EMA new marketing authorization application validated 2026` 3. **PRAC signals**: Search `EMA PRAC safety signal referral 2026` 4. **Priority pathologies**: Search each of these individually: - `TNBC triple negative breast cancer EMA regulatory 2026` - `hidradenitis suppurativa EMA CHMP 2026` - `rheumatoid arthritis EMA new treatment 2026` 5. **Adjacent pathologies**: Search `EMA CHMP negative opinion re-examination 2026` and `biosimilar CHMP positive opinion 2026` 6. **Clinical readouts**: Search `phase 3 results Europe oncology immunology 2026` For each finding, verify the regulatory trigger is SPECIFIC and RECENT (within the last week ideally). ### Phase 2: Target Selection & Prioritization Select exactly 8 targets following this STRICT priority framework: **PRIORITY 1 (minimum 3 targets):** Core pathologies — TNBC, Hidradenitis Suppurativa, Rheumatoid Arthritis. If fewer than 3 opportunities exist in these exact pathologies, expand to biologically adjacent areas: - TNBC adjacent: other breast cancers, ADC therapies, TROP2/HER2 targets - HS adjacent: atopic dermatitis, psoriasis, JAK inhibitor applications - RA adjacent: lupus, ankylosing spondylitis, psoriatic arthritis, other anti-TNF/JAK/IL-6 targets **PRIORITY 2 (minimum 2 targets):** Biologically adjacent pathologies — rare neuro, neuromuscular, pediatric rare diseases, immune-mediated inflammatory diseases. **PRIORITY 3 (minimum 3 targets):** Lowest-hanging fruits most compatible with ArcaScience technology — regardless of pathology: - Biosimilar evidence strategies (multi-indication, interchangeability) - CHMP negative opinions needing re-examination (HIGHEST VALUE — companies are desperate) - Complex multi-indication filings - Pediatric investigation plan challenges - Lifecycle management / Type II variations with evidence gaps ### Phase 3: Intelligence Compilation For EACH of the 8 targets, compile: 1. **Company**: Full legal entity name (EU subsidiary if applicable) 2. **Molecule**: INN (brand name) — include mechanism of action 3. **Indication**: Specific therapeutic indication under regulatory review 4. **Pathology**: Disease area 5. **Regulatory Status**: Current EMA/CHMP/PRAC status with exact dates 6. **Regulatory Trigger** (2-3 paragraphs): What happened, why it matters NOW, what the company needs. Be SPECIFIC — reference committee meeting dates, vote outcomes, methodology concerns raised, competitive dynamics. 7. **ArcaScience Narrative & Positioning** (3-4 bullet points): How ArcaScience SPECIFICALLY addresses this company's challenge. Reference concrete ArcaScience capabilities: - Evidence mapping & cross-indication harmonization - Regulatory gap analysis (pre-empting CHMP questions) - Endpoint & statistical narrative alignment - Bridging strategies (pediatric, geographic, cross-study) - Dynamic benefit-risk modeling (continuous vs. periodic) - Post-marketing RWE study design - Multi-indication HTA evidence strategy - Re-examination evidence reconstruction (for negative opinions) 8. **Key Contacts / Outreach Target**: Role titles and locations (EU regulatory affairs lead, CMO, VP PV, etc.). Reference the company dossiers in `arcascience_dossiers/companies/` if available. 9. **Outreach Email Template**: A COMPLETE, ready-to-send email (see Email Template Rules below). ### Phase 4: Document Generation Generate the report as a .docx file using docx-js. The file MUST follow this exact structure: #### Page 1: Cover - "ARCASCIENCE" (bold, large) - "DAILY COMMERCIAL INTELLIGENCE REPORT" - "European Regulatory Pulse — Targeted Opportunities" - Today's date - "8 Commercial Targets | 3 Priority Tiers | Europe Focus" #### Priority Legend - ● PRIORITY 1: TNBC | Hidradenitis Suppurativa | Rheumatoid Arthritis - ● PRIORITY 2: Biologically adjacent pathologies - ● PRIORITY 3: Lowest-hanging fruits — biosimilar evidence & lifecycle strategy #### Executive Summary 4-6 bullet points highlighting the KEY signals of the day. Emphasize: - Urgency (negative opinions, re-examinations, competitive races) - ArcaScience-specific relevance - Market size / strategic importance #### Targets #1 through #8 Each target gets its own section with all 9 elements from Phase 3. #### File naming `ArcaScience_Daily_Intel_YYYYMMDD.docx` Save to the workspace folder. ### Email Template Rules Every outreach email MUST follow this structure: ``` Subject: [Specific regulatory trigger] — [ArcaScience capability match] Dear [Role Title], [Opening paragraph: Reference the SPECIFIC regulatory event. Show you know what happened and why it matters to them. 2-3 sentences max.] [Value paragraph: Position ArcaScience as the solution to their specific challenge. Reference their pipeline, their regulatory history, their competitive context. 3-4 sentences.] Specifically, we can support: • [Capability 1 — tied to their specific situation] • [Capability 2 — tied to their specific situation] • [Capability 3 — tied to their specific situation] [Closing: Suggest a 30-minute call. Be specific about timing if possible.] Best regards, [Your name] ArcaScience ``` Rules: - NEVER use generic language like "your organization" or "companies like yours" - ALWAYS reference the specific molecule, indication, and regulatory event - ALWAYS include at least 3 specific capability bullets - Subject line must be under 80 characters and reference the trigger - Language: English (report and emails are always in English) ## References ### Embedded References (in this skill's references/ folder) - `references/arcascience-context.md` — Full company context & positioning - `references/sales-package-platform.md` — BRA platform deck, one-pagers, evidence infrastructure - `references/sales-package-proposals.md` — Client proposals (Dilon, Sanofi, Asphalion) & BRA analysis - `references/sales-package-personae.md` — Buyer personae analysis (14 personas with scoring) - `references/sales-package-operations.md` — Sales org process, contracts templates ### External Dossiers (in the GitHub repo — read on demand) - Company dossiers: `C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\companies\` (100 files) - Stakeholder profiles: `C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\stakeholders\` - Master targeting table: `C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\master_targeting_table.csv` - Company list: `C:\Users\Romai\OneDrive\Documents\GitHub\Decks-Docs\arcascience_dossiers\COMPANY_LIST.md` ## Quality Checklist (Self-Verify Before Delivering) - [ ] Exactly 8 targets (not 7, not 9) - [ ] At least 3 Priority 1, 2 Priority 2, 3 Priority 3 - [ ] Every regulatory trigger references a SPECIFIC event with a date - [ ] Every ArcaScience narrative has at least 3 SPECIFIC capability bullets - [ ] Every email template is customized (no copy-paste with name changes) - [ ] No targets older than 1 week unless re-examination is ongoing - [ ] .docx file is properly formatted and saved to workspace - [ ] File named ArcaScience_Daily_Intel_YYYYMMDD.docx


Security scan verdicts — ClawScan: clean | static analysis: clean | VirusTotal: clean | SkillSpector: error ()